ArticleDermatology and therapy2026

Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb Trial.

Nada Elbuluk et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.